Chris Holman speaks with David Weaver, CEO of Blaze Medical Devices, who gives a brief introduction on his company based out of Ann Arbor, Michigan. They discuss red blood cell damage and the importance of proper measurement when testing blood.

Blaze is developing technology to facilitate comprehensive and standardized assessment of blood cell properties, specifically for red blood cell (RBC) hemolysis and mechanical fragility. This technology will be utilized by hospitals, carriers and consumers and in the future, will be used for blood transfusions. David talks about his personal involvement with the device, the status of grant funding and the Great Lakes Angels, an angel investment firm that is based in Michigan, which makes equity investments in early state companies across the Great Lakes region.